Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01300-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Stefanie Hirsch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Hauptthemen laut MEDLINE: Tacrolimus, Lung Diseases, Interstitial, Dermatomyositis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Melanoma differentiation-associated protein 5 (MDA5) antibody positive amyopathic dermatomyositis (DM) is a rare inflammatory disease. So far, there is no official treatment guideline in MDA5 amyopathic dermatomyositis, but early and aggressive immunosuppressive combination treatment can induce a stable remission. We retrospectively analyzed a cohort of eight patients (male n = 5) that were diagnosed with MDA5-positive amyopathic DM. Patient data comprised demographics, CT-guided diagnosis of pulmonary involvement, pulmonary function testing including forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) data on baseline and mean long-term follow-up of 51 months (24–92 months) to evaluate treatment strategies. Depending on severity of organ involvement treatments were individualized including cyclophosphamide, immunoglobulins and plasmapheresis. Simultaneously, oral treatment with tacrolimus was commenced in four of the eight patients. Most patients received remission maintenance therapy with a combination of tacrolimus, rituximab and low dose steroids. In all patients, improvement in FVC was recorded and five patients achieved an improvement in DLCO. An improvement in the CT imaging morphological findings was observed in four patients. Awareness for the entirety of all clinical and disease-related findings of amyopathic DM is crucial, and remission maintenance is often achieved with a combination of tacrolimus and rituximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
- Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
- Department of Pneumology and Infectious Diseases, Hannover Medical School, Hannover, Germany.
- Department of Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Thiele.Thea@mh-hannover.de.
Förderung
- Deutsche Forschungsgemeinschaft
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Hirsch, S., Pöhler, G. H., Seeliger, B., Prasse, A., Witte, T., & Thiele, T. (2024). Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01300-8
Vancouver
Hirsch S, Pöhler GH, Seeliger B, Prasse A, Witte T, Thiele T. Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01300-8
BibTeX
@article{Hirsch2024,
author = {Hirsch, Stefanie and Pöhler, Gesa Helen and Seeliger, Benjamin and Prasse, Antje and Witte, Torsten and Thiele, Thea},
title = {Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01300-8}
}
EUVIMED